A Multicenter, Randomized, Double-blind, Placebo-Controlled Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia in Patients Receiving Long-term Milnacipran Treatment.

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-Controlled Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia in Patients Receiving Long-term Milnacipran Treatment.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jan 2013

At a glance

  • Drugs Milnacipran (Primary)
  • Indications Fibromyalgia
  • Focus Therapeutic Use
  • Sponsors Forest Laboratories
  • Most Recent Events

    • 28 Apr 2012 Results presented at the 64th Annual Meeting of the American Academy of Neurology.
    • 28 May 2011 Results presented at the 12th Annual Congress of the European League Against Rheumatism.
    • 11 Jun 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top